DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actonel (Risedronate Sodium) - Summary



ACTONEL (risedronate sodium tablets) is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each ACTONEL tablet for oral administration contains the equivalent of 5, 30, or 35 mg of anhydrous risedronate sodium in the form of the hemi-pentahydrate with small amounts of monohydrate.

ACTONEL is indicated for the following:


ACTONEL is indicated for the treatment and prevention of osteoporosis in postmenopausal women.


In postmenopausal women with osteoporosis, ACTONEL increases BMD and reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures (see CLINICAL STUDIES). Osteoporosis may be confirmed by the presence or history of osteoporotic fracture, or by the finding of low bone mass (for example, at least 2 SD below the premenopausal mean).


ACTONEL may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of fracture.

Factors such as family history of osteoporosis, previous fracture, smoking, BMD (at least 1 SD below the premenopausal mean), high bone turnover, thin body frame, Caucasian or Asian race, and early menopause are associated with an increased risk of developing osteoporosis and fractures. The presence of these risk factors may be important when considering the use of ACTONEL for prevention of osteoporosis.


ACTONEL is indicated for the prevention and treatment of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage equivalent to 7.5 mg or greater of prednisone) for chronic diseases. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D.


ACTONEL is indicated for treatment of Paget's disease of bone (osteitis deformans). Treatment is indicated in patients with Paget's disease of bone (1) who have a level of serum alkaline phosphatase at least 2 times the upper limit of normal, or (2) who are symptomatic, or (3) who are at risk for future complications from their disease, to induce remission (normalization of serum alkaline phosphatase).

See all Actonel indications & dosage >>


Published Studies Related to Actonel (Risedronate)

Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis. [2013]
bone markers in Korean patients with osteoporosis... CONCLUSION: A once-monthly pill of risedronate and cholecalciferol provided

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. [2013]
CONCLUSIONS: Weekly oral risedronate prevented BMD loss at 2 years and resulted

Lipid profiles within the SABRE trial of anastrozole with and without risedronate. [2012]
Lipid profiles in women with early breast cancer receiving anastrozole with or without risedronate were examined within an international Phase III/IV study to assess for possible treatment related changes. Postmenopausal women with hormone receptor-positive breast cancer were assigned to 1 of 3 strata by risk of fragility fracture...

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. [2012]
A 2-year, randomized, double-blind, placebo-controlled study in men with osteoporosis demonstrated that treatment with risedronate 35mg once a week significantly decreased bone turnover markers (BTMs) and increased bone mineral density (BMD). This study was extended to include a 2-year, open-label extension to continue to assess the safety and efficacy of risedronate in men with osteoporosis...

Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. [2012]
density (BMD) in patients with Crohn's disease... CONCLUSIONS: Risedronate, in addition to daily calcium and vitamin D

more studies >>

Clinical Trials Related to Actonel (Risedronate)

A Study of Actonel for the Prevention of Bone Loss [Completed]
The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.

Study Comparing Bone Loss in Women Who Take Calcium and Vitamin D With Women Who Also Take Risedronate or Exercise [Recruiting]
The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPE study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calcium and vitamin D plus participate in bone-loading exercises. Our central hypothesis is that improvements in bone health will be greater in women randomized to bone-loading exercises with calcium and vitamin D compared to women who take calcium and vitamin D only or women who take calcium and vitamin D plus risedronate.

Study to Evaluate the Safety and Efficacy of Denosumab and Actonel´┐Ż in Post Menopausal Women Transitioned From Alendronate Therapy [Completed]
A randomized, open label study to assess the safety and effectiveness of Denosumab, administered every 6 months and Actonel ® (Risedronate), administered monthly in post menopausal women transitioned from weekly or daily Alendronate therapy.

A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets [Active, not recruiting]
The present phase II/III, multicenter, randomized, double-blind, parallel group comparative study is designed to evaluate the efficacy and safety of oral administration of NE-58095NF(New formulation) tablets for 12 months in patients with involutional osteoporosis. For this study, patients receiving oral NE-58095 2. 5-mg tablets once daily for 12 months are set as the control group.

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer [Completed]
Prostate cancer patients treated with LHRH agonists (e. g., leuprolide) lose bone mineral density. This is similar to post-menopausal osteoporosis. Risedronate is approved to prevent osteoporosis. We hypothesize that risedronate may also be effective in prostate cancer patients treated with LHRH agonists.

more trials >>

Reports of Suspected Actonel (Risedronate) Side Effects

Femur Fracture (584)Fall (389)LOW Turnover Osteopathy (258)Arthralgia (232)Pain in Extremity (224)Stress Fracture (184)Osteoarthritis (174)Gastrooesophageal Reflux Disease (167)Osteonecrosis of JAW (166)Hypertension (159)more >>


Based on a total of 8 ratings/reviews, Actonel has an overall score of 5.88. The effectiveness score is 5.25 and the side effect score is 6.75. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.

Actonel review by 55 year old female patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   post-menopausal osteopenia
Dosage & duration:   35mg taken once a week for the period of Have been taking for 4 years now
Other conditions:   None
Other drugs taken:   None
Reported Results
Benefits:   My annual bone density scan improved significantly after my first year on Actonel. Although I still have osteopenia, my physician says Actonel is helping to maintain this improvement and it is keep me from progressing to osteoporosis.
Side effects:   I have not had any side effects, not even the heartburn that is the most common one.
Comments:   I take one 35 mg tab of Actonel first thing every Wednesday morning on an empty stomach with a full glass of water, sometimes 2 glasses. I wait at least 30 minutes before I eat or drink anything. While I am supposed to wait at least 30 minutes before lying down again, I confess that on a couple of Wednesday mornings when I was especially tired, I did lay back down. Even then, however, I did not experience any heartburn.


Actonel review by 62 year old female patient

Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   Moderate Side Effects
Treatment Info
Condition / reason:   improve bone density
Dosage & duration:   35 mg taken once per week for the period of 2 years
Other conditions:   none
Other drugs taken:   none
Reported Results
Benefits:   There was some leveling out of bone loss.
Side effects:   I started having problems with my right jaw clicking, something similar to TMJ. It went away completely when I stopped taking Actonel. Not sure if it was related, but it seemed odd that it stopped when I quit the drug.
Comments:   Mild osteopenia


Actonel review by 57 year old female patient

Overall rating:  
Effectiveness:   Ineffective
Side effects:   Severe Side Effects
Treatment Info
Condition / reason:   osteoporosis
Dosage & duration:   once a week (dosage frequency: 1 month) for the period of same
Other conditions:   Barrette's esophagus
Other drugs taken:   none
Reported Results
Benefits:   none since could not continue treatment & diagnosis was made from routine, post-menopausal bone-density test (I was not having symptoms).
Side effects:   severe indigestion/heart burn & increasing hoarseness
Comments:   Once a week on same day, take one tablet first thing in a.m. before eating with full glass water and do not lie down or eat anything for 30 mins.

See all Actonel reviews / ratings >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017